Advertisement
MRNA vs NVAX
Which Stock Would AI Choose? Moderna (MRNA) vs. Novavax (NVAX) Stock Comparison
Key Takeaways
- MRNA has delivered stronger year-to-date gains of around 64-70%, outperforming NVAX's 20% rise, reflecting broader market positioning in biotech.
- Both stocks experienced dips in recent weeks, with MRNA down about 3.5% over the past month and NVAX similarly volatile at around 8-9% decline.
- MRNA's market cap exceeds $19 billion, dwarfing NVAX's $1.3 billion, highlighting scale differences.
- Recent developments include NVAX's leadership changes and partnerships, while MRNA advances Phase 3 trials for new vaccines.
- Technical sentiment remains neutral for both, with potential catalysts ahead like earnings reports.
Introduction
Moderna (MRNA) and Novavax (NVAX) represent key players in the biotechnology sector, particularly in vaccine development using distinct technologies: mRNA for Moderna and protein-based platforms for Novavax. Both gained prominence during the COVID-19 pandemic but now navigate post-pandemic markets with diversified pipelines. This comparison is relevant for traders eyeing biotech volatility, growth investors seeking exposure to infectious disease innovations, and those monitoring relative performance amid shifting sentiment toward vaccine stocks. Recent market activity underscores contrasts in scale, momentum, and catalysts, aiding informed positioning.
MRNA Overview and Recent Performance
Moderna, Inc. (MRNA) is a biotechnology leader specializing in messenger RNA (mRNA) medicines, with products like Spikevax for COVID-19, RSV vaccines, and oncology therapeutics. Strategic alliances with Merck and others bolster its pipeline across respiratory, oncology, and rare diseases. In recent market activity, MRNA shares traded around $48-49, within a 52-week range of $22.28 to $59.55, supported by a market cap over $19 billion. Year-to-date gains reached 64-70%, though recent weeks saw a 3.5-9% pullback amid broader sector fluctuations and valuation scrutiny. Sentiment has been influenced by Phase 3 initiation for an H5 pandemic influenza vaccine and upcoming earnings, tempering volatility from prior surges. Negative EPS (earnings per share) of -7.26 reflects R&D investments, with neutral technicals signaling consolidation.
NVAX Overview and Recent Performance
Novavax, Inc. (NVAX) focuses on protein-based vaccines, commercializing Nuvaxovid for COVID-19 and partnering on malaria vaccines via its Matrix-M adjuvant. Collaborations with Sanofi, Pfizer, and Takeda enhance manufacturing and development. Shares recently hovered near $8, in a 52-week band of $5.80 to $11.97, with a $1.3 billion market cap. Year-to-date performance stood at about 20%, with recent weeks showing 8-9% declines amid market dips, though partnerships provided support. Key influences include a March executive appointment for R&D leadership and a Pfizer licensing deal yielding $30 million upfront, boosting revenue outlook to $230-270 million for 2026. Positive EPS of 2.58 and a low PE (price-to-earnings) ratio of 3.13 indicate relative value, with neutral technical sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top-performing AI trading bots from its library of over 351 bots that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current market conditions—analyzing real-time data for signals, risk management, and strategies like short-term scalping or longer-term trends—earn a spot among the 25 featured trending bots. These include AI Trading Signal Agents with no minimum balance, Virtual Agents for simulated customizable trading, and Brokerage Agents from live accounts. Bots vary by timeframe (e.g., 5min to 60min), volatility tolerance (low to high), and performance metrics tailored to sectors like biotech. Traders can filter by plan levels such as Intermediate or Expert to match styles. Visit Trending AI Robots to explore and copy top performers.
Head-to-Head Comparison
MRNA and NVAX both target infectious diseases but differ in technology: Moderna's mRNA platform enables rapid iteration and broader applications in oncology and rare diseases, versus Novavax's recombinant protein approach emphasizing adjuvants for enhanced immunity. Growth drivers contrast with MRNA's diversified late-stage pipeline and alliances versus NVAX's partnership-dependent revenue. Recent momentum favors MRNA's superior YTD returns, though NVAX offers value via lower valuation multiples. Risk factors include biotech volatility, regulatory hurdles, and funding needs, amplified for smaller NVAX (beta 1.96) over MRNA (beta 1.25). Sector exposure aligns in vaccines, but sentiment tilts toward Moderna's scale amid neutral technicals for both.
Tickeron AI Verdict
Tickeron's AI currently leans toward MRNA based on consistent trend strength, larger market positioning, and pipeline catalysts like influenza trials, positioning it better for relative outperformance in biotech rotations. NVAX shows promise from partnerships but trails in stability and momentum. This assessment reflects observable data patterns, with probabilities favoring sustained gains for MRNA over the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and NVAX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRNA’s FA Score shows that 1 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).
- MRNA’s FA Score: 1 green, 4 red.
- NVAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRNA’s TA Score shows that 4 TA indicator(s) are bullish while NVAX’s TA Score has 4 bullish TA indicator(s).
- MRNA’s TA Score: 4 bullish, 4 bearish.
- NVAX’s TA Score: 4 bullish, 6 bearish.
Price Growth
MRNA (@Biotechnology) experienced а +5.21% price change this week, while NVAX (@Biotechnology) price change was -6.43% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was -0.52%, and the average quarterly price growth was +2192.65%.
Reported Earning Dates
MRNA is expected to report earnings on Jul 30, 2026.
NVAX is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (+2.52% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MRNA | NVAX | MRNA / NVAX | |
| Capitalization | 19.8B | 1.46B | 1,356% |
| EBITDA | -2.88B | -42.13M | 6,830% |
| Gain YTD | 69.244 | 32.143 | 215% |
| P/E Ratio | N/A | 3.14 | - |
| Revenue | 2.2B | 596M | 370% |
| Total Cash | 5.21B | 790M | 659% |
| Total Debt | 1.3B | 295M | 440% |
MRNA | NVAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 41 | 51 | |
P/E GROWTH RATING 1..100 | 2 | 21 | |
SEASONALITY SCORE 1..100 | 75 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVAX's Valuation (76) in the Biotechnology industry is in the same range as MRNA (78). This means that NVAX’s stock grew similarly to MRNA’s over the last 12 months.
NVAX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRNA (100). This means that NVAX’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's SMR Rating (98) in the Biotechnology industry is in the same range as NVAX (100). This means that MRNA’s stock grew similarly to NVAX’s over the last 12 months.
MRNA's Price Growth Rating (41) in the Biotechnology industry is in the same range as NVAX (51). This means that MRNA’s stock grew similarly to NVAX’s over the last 12 months.
MRNA's P/E Growth Rating (2) in the Biotechnology industry is in the same range as NVAX (21). This means that MRNA’s stock grew similarly to NVAX’s over the last 12 months.
| MRNA | NVAX | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 86% |
| Stochastic ODDS (%) | 4 days ago 87% | 4 days ago 84% |
| Momentum ODDS (%) | 4 days ago 74% | 4 days ago 90% |
| MACD ODDS (%) | 4 days ago 78% | 4 days ago 89% |
| TrendWeek ODDS (%) | 4 days ago 78% | 4 days ago 87% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 86% |
| Advances ODDS (%) | 4 days ago 79% | 20 days ago 80% |
| Declines ODDS (%) | 14 days ago 87% | 8 days ago 87% |
| BollingerBands ODDS (%) | 4 days ago 76% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 83% | 4 days ago 86% |
Advertisement